Welcome to our dedicated page for Igm Biosciences SEC filings (Ticker: IGMS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The IGM Biosciences, Inc. (IGMS) SEC filings page on Stock Titan provides access to the company’s historical regulatory documents filed with the U.S. Securities and Exchange Commission. As a former Nasdaq-listed issuer, IGM Biosciences filed annual reports on Form 10‑K, quarterly reports on Form 10‑Q and current reports on Form 8‑K that describe its clinical-stage biotechnology activities, financial position, collaboration revenues, operating expenses and risk factors related to its engineered IgM antibody platform.
Among the notable filings is a Form 8‑K dated July 1, 2025, in which IGM Biosciences reports entering into an Agreement and Plan of Merger with Concentra Biosciences, LLC and a merger subsidiary. This filing outlines the structure of the cash tender offer and subsequent merger, the treatment of common stock, stock options, restricted stock units and certain pre‑funded warrants, and the creation of contingent value rights tied to closing net cash and potential future dispositions of specified product candidates and intellectual property.
Investors researching IGMS can also review a Form 25 filed with the SEC, which notifies the removal of IGM Biosciences’ common stock from listing and registration on The Nasdaq Stock Market LLC under Section 12(b) of the Securities Exchange Act of 1934. A later Form 15 filing certifies the termination of registration of the company’s common stock under Section 12(g) and the suspension of its duty to file reports under Sections 13 and 15(d), indicating that IGM Biosciences has deregistered its common stock and ceased ongoing Exchange Act reporting for that class of securities.
Stock Titan’s interface surfaces these filings in chronological order and can pair them with AI-powered summaries to highlight key points, such as changes in listing status, merger terms, cash thresholds, contingent value right mechanics and other material provisions. Users can quickly locate Forms 10‑K and 10‑Q for detailed historical financial and pipeline information, Forms 8‑K for material events, and the Form 25 and Form 15 that document the company’s transition from a publicly listed, reporting issuer to a wholly owned subsidiary following the Concentra transaction.
IGM Biosciences completed a merger and is removing unsold securities from registration. On August 14, 2025 the company merged with Concentra Merger Sub V, Inc., becoming a wholly owned subsidiary of Concentra Biosciences, LLC. Each outstanding public share (other than treasury shares, shares owned by Parent/Merger Sub, and any shares subject to valid appraisal rights) was converted into $1.247 cash per share plus one non-transferable contractual contingent value right per share.
As a result of the Merger and the termination of the company’s offerings, IGM is filing post-effective amendments to withdraw and remove any unissued and unsold securities previously registered on multiple Form S-8 registration statements and to terminate those registration statements.
IGM Biosciences completed a merger and terminated its Form S-8 offerings. Under a Merger Agreement dated July 1, 2025, the company merged into a subsidiary of Concentra Biosciences and became a wholly owned subsidiary of Parent on August 14, 2025. Each outstanding public share (with limited exceptions) converted into $1.247 in cash plus one non-transferable contractual contingent value right (CVR) per share. As a result, the registrant terminated all offerings under the referenced Form S-8 registration statements and filed post-effective amendments to withdraw and remove any unissued and unsold securities from registration.
IGM Biosciences has filed post-effective amendments to withdraw all unissued and unsold shares previously registered under multiple Form S-8 registration statements because the company completed a merger on August 14, 2025. Under the Merger Agreement, IGM became a wholly owned subsidiary of Concentra Biosciences, LLC; each outstanding common share (other than specified exceptions) was converted into $1.247 in cash and one non-transferable contractual contingent value right (CVR). As a result, the registrant terminated the planned securities offerings and removed remaining registered but unsold securities from registration.
IGM Biosciences, Inc. filed a Form 25 notifying the removal of its common stock from listing and/or registration on the Nasdaq Stock Market LLC. The filing includes statements that Nasdaq has complied with 17 CFR 240.12d2-2(b) and that the issuer has complied with 17 CFR 240.12d2-2(c) governing voluntary withdrawal. The document is signed by Tara Petta, AVP and dated 2025-08-14. The filing does not disclose an effective date for removal, the specific rule provision selected on the form, or the underlying reasons for the removal.
IGM Biosciences, Inc. amended its Schedule 14D-9 to report the final results of the tender offer by Concentra Biosciences, LLC. The Offer expired at one minute after 11:59 p.m., Eastern time, on August 13, 2025, and Broadridge advised Parent that 28,373,092 voting Shares were validly tendered and not validly withdrawn, representing approximately 77.53% of voting Shares outstanding at expiration. The tender satisfied the Minimum Tender Condition and all other Offer conditions were satisfied or waived. Parent accepted for payment all validly tendered Shares and expects to promptly pay the Offer Price of $1.247 per Share in cash plus one non-transferable contractual contingent value right (CVR). Pursuant to the Merger Agreement and Section 251(h) of the DGCL, Parent completed the Merger on August 14, 2025; outstanding Shares (with specified exceptions) were cancelled and converted into the right to receive the Offer Price, Shares ceased trading prior to Nasdaq open on August 14, 2025, and will be delisted and deregistered under the Exchange Act.
IGM Biosciences (IGMS) Form 4: CFO Misbah Tahir disclosed the sale of 8,741 common shares on 07/23/2025 at a weighted-average price of $1.2728 per share. The transaction was executed in multiple trades within a $1.27–$1.275 range and was explicitly undertaken to cover tax-withholding obligations associated with vesting restricted stock units (RSUs).
Following the sale, Tahir’s direct beneficial ownership stands at 170,061 shares. No derivative security transactions or additional acquisitions were reported. The filing represents a routine insider sale rather than a strategic disposition, and no other material events or financial metrics are included.
FAQ
What is the current stock price of Igm Biosciences (IGMS)?
What is the market cap of Igm Biosciences (IGMS)?
